{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:45:44Z","timestamp":1792075544130,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T00:00:00Z","timestamp":1783900800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T00:00:00Z","timestamp":1792022400000},"content-version":"vor","delay-in-days":94,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-16544-8","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T06:25:18Z","timestamp":1783923918000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Capmatinib and paclitaxel combination: a novel strategy for overcoming challenges in triple-negative breast cancer treatment"],"prefix":"10.1186","volume":"26","author":[{"given":"Ahmad Habibian","family":"Sezavar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Fakhari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emad","family":"Jafarzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vahideh","family":"Montazeri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Shadborestan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Abdollahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omid","family":"Sabzevari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abbas","family":"Kebriaeizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruhollah","family":"Hosseini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shima","family":"Aliebrahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Nasser","family":"Ostad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,13]]},"reference":[{"issue":"2","key":"16544_CR1","doi-asserted-by":"publisher","first-page":"241","DOI":"10.5858\/arpa.2013-0953-SA","volume":"138","author":"AC Wolff","year":"2014","unstructured":"Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, Allred DC, Bartlett JM, Bilous M, Fitzgibbons P. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241\u201356.","journal-title":"Arch Pathol Lab Med"},{"issue":"4","key":"16544_CR2","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/cncr.22836","volume":"110","author":"GJ Morris","year":"2007","unstructured":"Morris GJ, Naidu S, Topham AK, Guiles F, Xu Y, McCue P, Schwartz GF, Park PK, Rosenberg AL, Brill K. Differences in breast carcinoma characteristics in newly diagnosed African\u2013American and Caucasian patients: A single-institution compilation compared with the National Cancer Institute\u2019s Surveillance, Epidemiology, and end results database. Cancer: Interdisciplinary Int J Am Cancer Soc. 2007;110(4):876\u201384.","journal-title":"Cancer: Interdisciplinary Int J Am Cancer Soc"},{"issue":"10","key":"16544_CR3","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1158\/2159-8290.CD-13-0830","volume":"4","author":"A Stoeck","year":"2014","unstructured":"Stoeck A, Lejnine S, Truong A, Pan L, Wang H, Zang C, Yuan J, Ware C, MacLean J, Garrett-Engele PW. Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer Discov. 2014;4(10):1154\u201367.","journal-title":"Cancer Discov"},{"key":"16544_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00404-015-3859-y","volume":"293","author":"P Kumar","year":"2016","unstructured":"Kumar P, Aggarwal R. An overview of triple-negative breast cancer. Arch Gynecol Obstet. 2016;293:247\u201369.","journal-title":"Arch Gynecol Obstet"},{"key":"16544_CR5","doi-asserted-by":"publisher","unstructured":"Sezavar AH, Rastegar-Pouyani N, Rahimi Kakavandi N, Fakhari F, Jafarzadeh E, Aliebrahimi S, Ostad SN. Examining the relationship between per-and polyfluoroalkyl substances and breast, colorectal, prostate, and ovarian cancers: a meta-analysis. Crit Rev Toxicol. 2024:1\u201315. https:\/\/doi.org\/10.1080\/10408444.2024.2425669.","DOI":"10.1080\/10408444.2024.2425669"},{"issue":"1","key":"16544_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1568009033333754","volume":"3","author":"R Yusuf","year":"2003","unstructured":"Yusuf R, Duan Z, Lamendola D, Penson R, Seiden M. Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation. Curr Cancer Drug Targets. 2003;3(1):1\u201319.","journal-title":"Curr Cancer Drug Targets"},{"issue":"16","key":"16544_CR7","doi-asserted-by":"publisher","first-page":"5275","DOI":"10.1158\/1078-0432.CCR-10-2727","volume":"17","author":"R Sharpe","year":"2011","unstructured":"Sharpe R, Pearson A, Herrera-Abreu MT, Johnson D, Mackay A, Welti JC, Natrajan R, Reynolds AR, Reis-Filho JS, Ashworth A. FGFR signaling promotes the growth of triple-negative and basal-like breast cancer cell lines both in vitro and in vivo. Clin Cancer Res. 2011;17(16):5275\u201386.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"16544_CR8","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1038\/modpathol.3800528","volume":"19","author":"CA Livasy","year":"2006","unstructured":"Livasy CA, Karaca G, Nanda R, Tretiakova MS, Olopade OI, Moore DT, Perou CM. Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Mod Pathol. 2006;19(2):264\u201371.","journal-title":"Mod Pathol"},{"key":"16544_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-018-0796-y","volume":"17","author":"Y Zhang","year":"2018","unstructured":"Zhang Y, Xia M, Jin K, Wang S, Wei H, Fan C, Wu Y, Li X, Li X, Li G. Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities. Mol Cancer. 2018;17:1\u201314.","journal-title":"Mol Cancer"},{"key":"16544_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-015-0547-6","volume":"17","author":"CM Ho-Yen","year":"2015","unstructured":"Ho-Yen CM, Jones JL, Kermorgant S. The clinical and functional significance of c-Met in breast cancer: a review. Breast Cancer Res. 2015;17:1\u201311.","journal-title":"Breast Cancer Res"},{"issue":"2","key":"16544_CR11","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1158\/2159-8290.CD-13-0286","volume":"4","author":"JM Balko","year":"2014","unstructured":"Balko JM, Giltnane JM, Wang K, Schwarz LJ, Young CD, Cook RS, Owens P, Sanders ME, Kuba MG, S\u00e1nchez V. Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. Cancer Discov. 2014;4(2):232\u201345.","journal-title":"Cancer Discov"},{"issue":"8","key":"16544_CR12","doi-asserted-by":"publisher","first-page":"3397","DOI":"10.4251\/wjgo.v16.i8.3397","volume":"16","author":"W-J Wei","year":"2024","unstructured":"Wei W-J, Hong Y-L, Deng Y, Wang G-L, Qiu J-T, Pan F. Research progress on the development of hepatocyte growth factor\/c-Met signaling pathway in gastric cancer: A review. World J Gastrointest Oncol. 2024;16(8):3397.","journal-title":"World J Gastrointest Oncol"},{"issue":"7","key":"16544_CR13","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1007\/s10585-013-9585-6","volume":"30","author":"RR Mehta","year":"2013","unstructured":"Mehta RR, Katta H, Kalra A, Patel R, Gupta A, Alimirah F, Murillo G, Peng X, Unni A, Muzzio M. Efficacy and mechanism of action of Deguelin in suppressing metastasis of 4T1 cells. Clin Exp Metast. 2013;30(7):855\u201366.","journal-title":"Clin Exp Metast"},{"key":"16544_CR14","doi-asserted-by":"crossref","unstructured":"Lefebvre C, Allan AL. Anti-proliferative and anti-migratory effects of EGFR and c-Met tyrosine kinase inhibitors in triple negative breast cancer cells. Precision Cancer Med. 2021;4. https:\/\/pcm.amegroups.org\/article\/view\/6035\/html.","DOI":"10.21037\/pcm-20-62"},{"key":"16544_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.bbacli.2015.03.003","volume":"3","author":"EA O\u2019Reilly","year":"2015","unstructured":"O\u2019Reilly EA, Gubbins L, Sharma S, Tully R, Guang MHZ, Weiner-Gorzel K, McCaffrey J, Harrison M, Furlong F, Kell M. The fate of chemoresistance in triple negative breast cancer (TNBC). BBA Clin. 2015;3:257\u201375.","journal-title":"BBA Clin"},{"key":"16544_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.ctrv.2016.09.004","volume":"50","author":"F Schettini","year":"2016","unstructured":"Schettini F, Giuliano M, De Placido S, Arpino G. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives. Cancer Treat Rev. 2016;50:129\u201341.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"16544_CR17","first-page":"355","volume":"19","author":"V Montazeri","year":"2020","unstructured":"Montazeri V, Ghahremani MH, Montazeri H, Hasanzad M, Ayati M, Chehrazi M, Moghaddam BA, Ostad SN. A preliminary study of NER and MMR pathways involved in chemotherapy response in bladder transitional cell carcinoma: impact on progression-free survival. Iran J Pharm Research: IJPR. 2020;19(1):355.","journal-title":"Iran J Pharm Research: IJPR"},{"key":"16544_CR18","doi-asserted-by":"crossref","unstructured":"Newton EE, Mueller LE, Treadwell SM, Morris CA, Machado HL. Molecular Targets of triple-negative breast cancer: where do we stand? Cancers (Basel). 2022;14(3). https:\/\/www.mdpi.com\/2072-6694\/14\/3\/482.","DOI":"10.3390\/cancers14030482"},{"issue":"7","key":"16544_CR19","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1080\/07357907.2023.2237576","volume":"41","author":"N Rastegar-Pouyani","year":"2023","unstructured":"Rastegar-Pouyani N, Montazeri V, Marandi N, Aliebrahimi S, Andalib M, Jafarzadeh E, Montazeri H, Ostad SN. The impact of cancer-associated fibroblasts on drug resistance, stemness, and epithelial-mesenchymal transition in bladder cancer: a comparison between recurrent and non-recurrent patient-derived Cafs. Cancer Invest. 2023;41(7):656\u201371.","journal-title":"Cancer Invest"},{"issue":"6","key":"16544_CR20","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1016\/j.plefa.2014.09.002","volume":"91","author":"O Galindo-Hernandez","year":"2014","unstructured":"Galindo-Hernandez O, Serna-Marquez N, Castillo-Sanchez R, Salazar EP. Extracellular vesicles from MDA-MB-231 breast cancer cells stimulated with linoleic acid promote an EMT-like process in MCF10A cells. Prostaglandins Leukot Essent Fatty Acids. 2014;91(6):299\u2013310.","journal-title":"Prostaglandins Leukot Essent Fatty Acids"},{"issue":"8Supplement","key":"16544_CR21","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1158\/1538-7445.AM2013-876","volume":"73","author":"AA Sprouse","year":"2013","unstructured":"Sprouse AA, Herbert B-S. Molecular mechanisms of paclitaxel-resistance and resveratrol sensitivity in MDA-MB-231 breast cancer cells. Cancer Res. 2013;73(8Supplement):876\u2013876.","journal-title":"Cancer Res"},{"issue":"5","key":"16544_CR22","doi-asserted-by":"publisher","first-page":"2277","DOI":"10.21873\/anticanres.13344","volume":"39","author":"HI Atiya","year":"2019","unstructured":"Atiya HI, Dvorkin-Gheva A, Hassell J, Patel S, Parker RL, Hartstone-Rose A, Hodge J, Fan D, Ramsdell AF. Intraductal adaptation of the 4T1 mouse model of breast cancer reveals effects of the epithelial microenvironment on tumor progression and metastasis. Anticancer Res. 2019;39(5):2277\u201387.","journal-title":"Anticancer Res"},{"issue":"1","key":"16544_CR23","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1186\/s12967-025-06367-9","volume":"23","author":"Y Hong","year":"2025","unstructured":"Hong Y, He J, Deng D, Liu Q, Zu X, Shen Y. Targeting kinases that regulate programmed cell death: a new therapeutic strategy for breast cancer. J Transl Med. 2025;23(1):439.","journal-title":"J Transl Med"},{"issue":"1","key":"16544_CR24","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13046-023-02866-z","volume":"42","author":"S Kim","year":"2023","unstructured":"Kim S, Park JM, Park S, Jung E, Ko D, Park M, Seo J, Nam KD, Kang YK, Lee K. Suppression of TNBC metastasis by doxazosin, a novel dual inhibitor of c-MET\/EGFR. J Experimental Clin Cancer Res. 2023;42(1):292.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"1","key":"16544_CR25","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1007\/s11033-024-09572-9","volume":"51","author":"SG Dehbokri","year":"2024","unstructured":"Dehbokri SG, Noorolyai S, Baghbani E, Moghaddamneshat N, Javaheri T, Baradaran B. Effects of CD44 siRNA on inhibition, survival, and apoptosis of breast cancer cell lines (MDA-MB-231 and 4T1). Mol Biol Rep. 2024;51(1):646.","journal-title":"Mol Biol Rep"},{"issue":"1","key":"16544_CR26","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1186\/s12885-022-10119-z","volume":"22","author":"BM Haynes","year":"2022","unstructured":"Haynes BM, Cunningham K, Shekhar MP. RAD6 inhibition enhances paclitaxel sensitivity of triple negative breast cancer cells by aggravating mitotic spindle damage. BMC Cancer. 2022;22(1):1073.","journal-title":"BMC Cancer"},{"key":"16544_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W, Yu S. -c: Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:1\u201313.","journal-title":"Breast Cancer Res"},{"issue":"5","key":"16544_CR28","doi-asserted-by":"publisher","first-page":"e97622","DOI":"10.1371\/journal.pone.0097622","volume":"9","author":"MR Akl","year":"2014","unstructured":"Akl MR, Ayoub NM, Mohyeldin MM, Busnena BA, Foudah AI, Liu Y-Y, Sayed KAE. Olive phenolics as c-Met inhibitors:(-)-Oleocanthal attenuates cell proliferation, invasiveness, and tumor growth in breast cancer models. PLoS ONE. 2014;9(5):e97622.","journal-title":"PLoS ONE"},{"issue":"8","key":"16544_CR29","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1080\/01635581.2017.1367936","volume":"69","author":"HE Elsayed","year":"2017","unstructured":"Elsayed HE, Ebrahim HY, Mohyeldin MM, Siddique AB, Kamal AM, Haggag EG, El Sayed KA. Rutin as A Novel c-Met Inhibitory Lead for The Control of Triple Negative Breast Malignancies. Nutr Cancer. 2017;69(8):1256\u201371.","journal-title":"Nutr Cancer"},{"issue":"18","key":"16544_CR30","doi-asserted-by":"publisher","first-page":"15966","DOI":"10.18632\/oncotarget.3862","volume":"6","author":"C-Y Liu","year":"2015","unstructured":"Liu C-Y, Lin H-H, Tang M-J, Wang Y-K. Vimentin contributes to epithelial-mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget. 2015;6(18):15966.","journal-title":"Oncotarget"},{"issue":"6","key":"16544_CR31","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3892\/ol.2023.13857","volume":"25","author":"W Wang","year":"2023","unstructured":"Wang W, Jin J, Zhou Z, Wang Y, Min K, Zuo X, Jiang J, Zhou Y, Shi J. Snail inhibits metastasis via regulation of E\u2013cadherin and is associated with prognosis in colorectal cancer. Oncol Lett. 2023;25(6):271.","journal-title":"Oncol Lett"},{"issue":"8","key":"16544_CR32","first-page":"1642","volume":"7","author":"X Zhu","year":"2017","unstructured":"Zhu X, Wei L, Bai Y, Wu S, Han S. FoxC1 promotes epithelial-mesenchymal transition through PBX1 dependent transactivation of ZEB2 in esophageal cancer. Am J Cancer Res. 2017;7(8):1642.","journal-title":"Am J Cancer Res"},{"issue":"3","key":"16544_CR33","first-page":"1297","volume":"9","author":"L Huang","year":"2017","unstructured":"Huang L, Huang Z, Fan Y, He L, Ye M, Shi K, Ji B, Huang J, Wang Y, Li Q. FOXC1 promotes proliferation and epithelial-mesenchymal transition in cervical carcinoma through the PI3K-AKT signal pathway. Am J translational Res. 2017;9(3):1297.","journal-title":"Am J translational Res"},{"key":"16544_CR34","unstructured":"Song X-F, Chang H, Liang Q, Guo Z-F, Wu J-W. ZEB1 promotes prostate cancer proliferation and invasion through ERK1\/2 signaling pathway. Eur Rev Med Pharmacol Sci. 2017;21(18). https:\/\/www.europeanreview.org\/wp\/wp-content\/uploads\/4032-4038-ZEB1-facilitates-prostate-cancer-malignancy.pdf."},{"issue":"6","key":"16544_CR35","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.3892\/ijmm.2014.1707","volume":"33","author":"Y Wang","year":"2014","unstructured":"Wang Y, Yao B, Wang Y, Zhang M, Fu S, Gao H, Peng R, Zhang L, Tang J. Increased FoxM1 expression is a target for metformin in the suppression of EMT in prostate cancer. Int J Mol Med. 2014;33(6):1514\u201322.","journal-title":"Int J Mol Med"},{"issue":"6","key":"16544_CR36","doi-asserted-by":"publisher","first-page":"2660","DOI":"10.3892\/or.2014.3129","volume":"31","author":"F-F Kong","year":"2014","unstructured":"Kong F-F, Qu Z-Q, Yuan H-H, Wang J-Y, Zhao M, Guo Y-H, Shi J, Gong X-D, Zhu Y-L, Liu F. Overexpression of FOXM1 is associated with EMT and is a predictor of poor prognosis in non-small cell lung cancer. Oncol Rep. 2014;31(6):2660\u20138.","journal-title":"Oncol Rep"},{"key":"16544_CR37","doi-asserted-by":"publisher","unstructured":"Zhu L, Pan R, Zhou D, Ye G, Tan W. BCL11A enhances stemness and promotes progression by activating Wnt\/\u03b2-catenin signaling in breast cancer. Cancer Manage Res. 2019:2997\u20133007. https:\/\/doi.org\/10.2147\/CMAR.S199368.","DOI":"10.2147\/CMAR.S199368"},{"issue":"5","key":"16544_CR38","doi-asserted-by":"publisher","first-page":"2442","DOI":"10.7150\/thno.46460","volume":"11","author":"H Wang","year":"2021","unstructured":"Wang H, Guo S, Kim S-J, Shao F, Ho JWK, Wong KU, Miao Z, Hao D, Zhao M, Xu J. Cisplatin prevents breast cancer metastasis through blocking early EMT and retards cancer growth together with paclitaxel. Theranostics. 2021;11(5):2442.","journal-title":"Theranostics"},{"issue":"2","key":"16544_CR39","doi-asserted-by":"publisher","first-page":"50","DOI":"10.3892\/ol.2021.13168","volume":"23","author":"J Esparza-L\u00f3pez","year":"2022","unstructured":"Esparza-L\u00f3pez J, Longoria O, De La Cruz-Escobar EN, Garibay-D\u00edaz JC, Le\u00f3n-Rodr\u00edguez E. De Jes\u00fas Ibarra-S\u00e1nchez M: Paclitaxel resistance is mediated by NF-\u03baB on mesenchymal primary breast cancer cells. Oncol Lett. 2022;23(2):50.","journal-title":"Oncol Lett"},{"issue":"35","key":"16544_CR40","doi-asserted-by":"publisher","first-page":"37526","DOI":"10.18632\/oncotarget.6063","volume":"6","author":"S-Y Park","year":"2015","unstructured":"Park S-Y, Kim M-J, Park S-A, Kim J-S, Min K-N, Kim D-K, Lim W, Nam J-S, Sheen YY. Combinatorial TGF-\u03b2 attenuation with paclitaxel inhibits the epithelial-to-mesenchymal transition and breast cancer stem-like cells. Oncotarget. 2015;6(35):37526.","journal-title":"Oncotarget"},{"issue":"20","key":"16544_CR41","doi-asserted-by":"publisher","first-page":"4978","DOI":"10.3390\/cancers14204978","volume":"14","author":"MH Yang","year":"2022","unstructured":"Yang MH, Mohan CD, Deivasigamani A, Chinnathambi A, Alharbi SA, Rangappa KS, Jung SH, Ko H, Hui KM, Sethi G. Procaine abrogates the epithelial-mesenchymal transition process through modulating c-met phosphorylation in hepatocellular carcinoma. Cancers. 2022;14(20):4978.","journal-title":"Cancers"},{"issue":"4","key":"16544_CR42","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1158\/1078-0432.CCR-15-0187","volume":"22","author":"M Sameni","year":"2016","unstructured":"Sameni M, Tovar EA, Essenburg CJ, Chalasani A, Linklater ES, Borgman A, Cherba DM, Anbalagan A, Winn ME, Graveel CR. Cabozantinib (XL184) inhibits growth and invasion of preclinical TNBC models. Clin Cancer Res. 2016;22(4):923\u201334.","journal-title":"Clin Cancer Res"},{"key":"16544_CR43","doi-asserted-by":"crossref","unstructured":"Khan Y, Rizvi S, Raza A, Khan A, Hussain S, Khan NU, Alshammari SO, Alshammari QA, Alshammari A, Ellakwa DE-S. Tailored therapies for triple-negative breast cancer: current landscape and future perceptions. Naunyn Schmiedebergs Arch Pharmacol. 2025:1\u201326. https:\/\/link.springer.com\/article\/10.1007\/s00210-025-03896-4.","DOI":"10.1007\/s00210-025-03896-4"},{"key":"16544_CR44","doi-asserted-by":"publisher","first-page":"221","DOI":"10.3389\/fonc.2020.00221","volume":"10","author":"Y Haibe","year":"2020","unstructured":"Haibe Y, Kreidieh M, El Hajj H, Khalifeh I, Mukherji D, Temraz S, Shamseddine A. Resistance mechanisms to anti-angiogenic therapies in cancer. Front Oncol. 2020;10:221.","journal-title":"Front Oncol"},{"issue":"30","key":"16544_CR45","doi-asserted-by":"publisher","first-page":"4181","DOI":"10.1038\/s41388-018-0256-6","volume":"37","author":"AA Gl\u00fcck","year":"2018","unstructured":"Gl\u00fcck AA, Orlando E, Leiser D, Poliakov\u00e1 M, Nisa L, Quintin A, Gavini J, Stroka DM, Berezowska S, Bubendorf L. Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1\u03b1 levels under hypoxia. Oncogene. 2018;37(30):4181\u201396.","journal-title":"Oncogene"},{"issue":"aop","key":"16544_CR46","first-page":"1","volume":"1","author":"X Yang","year":"2024","unstructured":"Yang X, Li X, Yan J, Liu Y, Yin J, Shao W, Lu Y, Xue J. Response to EGFR\/NTRK\/MET Co-Inhibition Guided by Paired NGS in Advanced NSCLC With Acquired EGFR L858R\/T790M\/C797S Mutations. J Natl Compr Canc Netw. 2024;1(aop):1\u20137.","journal-title":"J Natl Compr Canc Netw"},{"key":"16544_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13046-019-1035-0","volume":"38","author":"PP Vitiello","year":"2019","unstructured":"Vitiello PP, Cardone C, Martini G, Ciardiello D, Belli V, Matrone N, Barra G, Napolitano S, Della Corte C, Turano M. Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR\/RAS\/MAPK pathway in KRAS-mutated human colorectal cancer cell lines. J Experimental Clin Cancer Res. 2019;38:1\u201312.","journal-title":"J Experimental Clin Cancer Res"},{"issue":"9","key":"16544_CR48","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.4049\/jimmunol.2100500","volume":"209","author":"NJ Shields","year":"2022","unstructured":"Shields NJ, Peyroux EM, Campbell K, Mehta S, Woolley AG, Counoupas C, Neumann S, Young SL. Calpains Released from Necrotic Tumor Cells Enhance Antigen Cross-Presentation to Activate CD8\u2009+\u2009T Cells In Vitro. J Immunol. 2022;209(9):1635\u201351.","journal-title":"J Immunol"},{"issue":"41","key":"16544_CR49","doi-asserted-by":"publisher","first-page":"17218","DOI":"10.1039\/D1NR05512G","volume":"13","author":"M Jiang","year":"2021","unstructured":"Jiang M, Zeng J, Zhao L, Zhang M, Ma J, Guan X, Zhang W. Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo\u2013immunotherapy. Nanoscale. 2021;13(41):17218\u201335.","journal-title":"Nanoscale"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16544-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16544-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-16544-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:02:44Z","timestamp":1792072964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-16544-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,13]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["16544"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-16544-8","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,13]]},"assertion":[{"value":"18 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1234"}}